Drug intelligence / Profile preview

COVIDAX

Development stage: Unknown
Lead developer: Axon Neuroscience
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

**COVIDAX** is an investigational peptide-based prophylactic COVID-19 vaccine developed by **AXON Neuroscience**. It is designed from selected short peptide epitopes derived from the **SARS-CoV-2 spike glycoprotein** and aims to induce neutralizing antibody responses that block viral interaction with host cells. The program was reported to have shown positive preclinical activity in mice, including generation of antibodies capable of neutralizing live SARS-CoV-2 virus, and was planned to enter Phase 1 clinical testing in late 2020.

Brand names: COVIDAX

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on COVIDAX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVIDAX.

Explore the full profile